Cooling the flames, clearing the airways: systemic inflammation in the era of elexacaftor/tezacaftor/ivacaftor

Chanhee Seo¹, Christina S Thornton^{2

3}

Affiliations

¹ Division of Respirology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
² Division of Respiratory Medicine, Department of Medicine, University of Calgary, Calgary, AB, Canada christina.thornton@albertahealthservices.ca.
³ Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada.

Editorial

Chanhee Seo et al. Eur Respir J. 2025.

. 2025 Dec 4;66(6):2501805.

doi: 10.1183/13993003.01805-2025. Print 2025 Dec.

Chanhee Seo¹, Christina S Thornton^{2

3}

¹ Division of Respirology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
² Division of Respiratory Medicine, Department of Medicine, University of Calgary, Calgary, AB, Canada christina.thornton@albertahealthservices.ca.
³ Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada.

No abstract available

Conflict of interest statement

Conflict of interest: The authors have no potential conflicts of interest to disclose.

Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis.
Halle O, Graeber SY, Kontsendorn J, Kessemeier C, Falke JN, Schwabe J, Schütz K, Pallenberg ST, Dalferth R, Grychtol R, Ringshausen FC, Stahl M, Thee S, Roehmel JF, Syunyaeva Z, Duerr J, Chung J, Hirtz S, Uselmann T, Kühbandner I, Rückes-Nilges C, Bagheri-Pothoff A, Barth S, Schaub B, Brinkmann F, Weber S, van Koningsbruggen-Rietschel S, Abdo M, Weckmann M, Widder S, Hansen G, Tümmler B, Sommerburg O, Naehrlich L, Mall MA, Dittrich AM. Halle O, et al. Eur Respir J. 2025 Dec 4;66(6):2500150. doi: 10.1183/13993003.00150-2025. Print 2025 Dec. Eur Respir J. 2025. PMID: 40967763 Free PMC article.